Literature DB >> 17716176

Magnetic and fluorescent nanoparticles for multimodality imaging.

Willem J M Mulder1, Arjan W Griffioen, Gustav J Strijkers, David P Cormode, Klaas Nicolay, Zahi A Fayad.   

Abstract

The development of nanoparticulate contrast agents is providing an increasing contribution to the field of diagnostic and molecular imaging. Such agents provide several advantages over traditional compounds. First, they may contain a high payload of the contrast-generating material, which greatly improves their detectability. Second, multiple properties may be easily integrated within one nanoparticle to allow its detection with several imaging techniques or to include therapeutic qualities. Finally, the surface of such nanoparticles may be modified to improve circulation half-lives or to attach targeting groups. Magnetic resonance imaging and optical techniques are highly complementary imaging methods. Combining these techniques would therefore have significant advantages and may be realized through the use of nanoparticulate contrast agents. This review gives a survey of the different types of fluorescent and magnetic nanoparticles that have been employed for both magnetic resonance and optical imaging studies.

Mesh:

Substances:

Year:  2007        PMID: 17716176     DOI: 10.2217/17435889.2.3.307

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  39 in total

1.  An activatable multimodal/multifunctional nanoprobe for direct imaging of intracellular drug delivery.

Authors:  Rajendra N Mitra; Mona Doshi; Xiaolei Zhang; Jessica C Tyus; Niclas Bengtsson; Steven Fletcher; Brent D G Page; James Turkson; Andre J Gesquiere; Patrick T Gunning; Glenn A Walter; Swadeshmukul Santra
Journal:  Biomaterials       Date:  2011-11-10       Impact factor: 12.479

Review 2.  Near-infrared fluorescent nanoprobes for cancer molecular imaging: status and challenges.

Authors:  Xiaoxiao He; Jinhao Gao; Sanjiv Sam Gambhir; Zhen Cheng
Journal:  Trends Mol Med       Date:  2010-10-01       Impact factor: 11.951

Review 3.  Nanocarriers for tracking and treating diseases.

Authors:  Sean Marrache; Rakesh Kumar Pathak; Kasey L Darley; Joshua H Choi; Dhillon Zaver; Nagesh Kolishetti; Shanta Dhar
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

Review 4.  Perspectives and opportunities for nanomedicine in the management of atherosclerosis.

Authors:  Mark E Lobatto; Valentin Fuster; Zahi A Fayad; Willem J M Mulder
Journal:  Nat Rev Drug Discov       Date:  2011-10-21       Impact factor: 84.694

Review 5.  Gold nanoclusters as novel optical probes for in vitro and in vivo fluorescence imaging.

Authors:  Li Shang; G Ulrich Nienhaus
Journal:  Biophys Rev       Date:  2012-04-12

Review 6.  Multiplexed Optical Imaging of Energy Substrates Reveals That Left Ventricular Hypertrophy Is Associated With Brown Adipose Tissue Activation.

Authors:  Marcello Panagia; Howard H Chen; Dominique Croteau; Yin-Ching Iris Chen; Chongzhao Ran; Ivan Luptak; Lee Josephson; Wilson S Colucci; David E Sosnovik
Journal:  Circ Cardiovasc Imaging       Date:  2018-03       Impact factor: 7.792

Review 7.  Targeted nanoparticles for colorectal cancer.

Authors:  Bruno A Cisterna; Nazila Kamaly; Won Il Choi; Ali Tavakkoli; Omid C Farokhzad; Cristian Vilos
Journal:  Nanomedicine (Lond)       Date:  2016-08-16       Impact factor: 5.307

8.  Dextran coated bismuth-iron oxide nanohybrid contrast agents for computed tomography and magnetic resonance imaging.

Authors:  Pratap C Naha; Ajlan Al Zaki; Elizabeth Hecht; Michael Chorny; Peter Chhour; Eric Blankemeyer; Douglas M Yates; Walter R T Witschey; Harold I Litt; Andrew Tsourkas; David P Cormode
Journal:  J Mater Chem B       Date:  2014-12-14       Impact factor: 6.331

Review 9.  Modified natural nanoparticles as contrast agents for medical imaging.

Authors:  David P Cormode; Peter A Jarzyna; Willem J M Mulder; Zahi A Fayad
Journal:  Adv Drug Deliv Rev       Date:  2009-11-06       Impact factor: 15.470

10.  Monocyte-directed RNAi targeting CCR2 improves infarct healing in atherosclerosis-prone mice.

Authors:  Maulik D Majmudar; Edmund J Keliher; Timo Heidt; Florian Leuschner; Jessica Truelove; Brena F Sena; Rostic Gorbatov; Yoshiko Iwamoto; Partha Dutta; Gregory Wojtkiewicz; Gabriel Courties; Matt Sebas; Anna Borodovsky; Kevin Fitzgerald; Marc W Nolte; Gerhard Dickneite; John W Chen; Daniel G Anderson; Filip K Swirski; Ralph Weissleder; Matthias Nahrendorf
Journal:  Circulation       Date:  2013-04-24       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.